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The purpose of this study was to assess the factors that influence ART adherence arising in rural settings in
Zambia. A survey was conducted with face-to-face interviews using a semi-structured questionnaire and written
informed consent was obtained at ART sites in Mumbwa District in rural Zambia. The questionnaire included
items such as the socio-demographic characteristics of respondents, support for adherence, ways to remember
when to take ARVs at scheduled times, and the current status of adherence. Valid responses were obtained from
518 research participants. The mean age of the respondents was 38.3 years and the average treatment period was
12.5 months. More than half of the respondents (51%) were farmers, about half (49%) did not own a watch, and
10% of them used the position of the sun to remember when to take ARVs. Sixteen percent of respondents
experienced fear of stigma resulting from taking ARVs at work or home, and 10% felt pressured to share ARVs
with someone. Eighty-eight percent of the participants reported that they had never missed ARVs in the past four
days. Multivariable logistic regression analysis identified age (38 years old or less, odds ratio (OR) 2.5, 95%
confidence interval (CI): 1.34.8, p0.005), ‘‘remembering when to take ARVs based on the position of the sun’’
(OR 3.3, 95% CI: 1.38.8, p0.016), and ‘‘feeling pressured to share ARVs with someone’’ (OR 4.4, 95%
CI: 1.612.0, p0.004) as independent factors for low adherence. As ART services expand to rural areas,
program implementers should pay more attention to more specific factors arising in rural settings since they may
differ from those in urban settings.
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Introduction
By December 2007, almost three million people living
with HIV (PLWH) were estimated to be receiving
antiretroviral therapy (ART) in low- and middle-
income countries, representing 30% of the estimated
population needing antiretrovirals (ARVs) in 2007.
Sub-Saharan Africa is now estimated to have more
than two million people on ART although four years
ago there were 100,000 people on ART and coverage
amounted to only 2% (United Nations, 2008).
Zambia is one of the sub-Saharan African coun-
tries worst affected by the HIV pandemic. Adult HIV
prevalence is about 14% and the number of PLWH is
estimated to be 1.2 million (Central Statistic Office
et al., 2009). In August 2005, the Zambian Govern-
ment announced free provision of ARVs to those who
are in need in an attempt to achieve the national
target of the ‘‘3 by 5’’ initiatives followed by the
Universal Access targets. Out of the estimated
280,000 PLWH who are in need of ART, nearly
half are believed to have used ART services prior to
the end of 2007 (UNAIDS, 2008). ART services have
been expanded nationwide in Zambia and conse-
quently ART has become increasingly accessible to
PLWH in rural areas as well.
Given the living conditions in rural areas, the
situation for PLWH in rural Zambia differs substan-
tially from that in urban areas or in developed
countries. Those differences should be taken into
consideration to devise successful ART expansion
programs.
ART adherence is now considered crucial for
HIV-positive individuals receiving therapy and an
important component for an ART program to
succeed. Intervention strategies to support adherence
have been found to be important in the achievement
of positive outcomes (Amico et al., 2006). Consis-
tently, high levels of adherence are needed for reliable
viral suppression (Bangsberg et al., 2000; Paterson
et al., 2000) and to prevent drug resistance (Bangs-
berg et al., 2003; Hecht et al., 1998; Pillay, 2001),
disease progression (Bangsberg et al., 2001), and
death (Garcia de Olalla et al., 2002; Wood et al.,
2003). Many factors, including complicated therapeu-
tic regimens, depression, alcohol and drug use, and
changes in daily routines may reportedly impact a
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(Chesney et al., 2000; Kleeberger et al., 2001). In
Zambia, several reports demonstrated factors asso-
ciated with adherence in rural settings (Birbeck et al.,
2009; Carlucci et al., 2008). However, no reports have
examined more specific social issues in rural settings
as factors influencing adherence to ART. Thus,
this study investigated adherence to ART in rural
settings in Zambia and assessed social and specific
factors that may influence ART adherence in rural
settings in order to help improve ART expansion
strategies to better suit rural settings.
Methods
Study site
This study was conducted in Mumbwa District,
which is located 150 km west of the capital and has
a district hospital and 27 rural health centers, where
the Ministry of Health has been expanding ART
services. Among the health facilities, services were
available only at the district hospital and four rural
health centers that had approximately 2000 ART
clients in total.
Study participants and procedures
Between 25 March and 25 April 2008, all ART clients
aged 18 and over that came to the hospital or one of
the four rural health centers where ART services were
offered were asked to participate in the study. Prior to
participation in the study, informed consent was
obtained by trained interviewers.
A cross-sectional survey with a semi-structured
questionnaire with face-to-face interviews was admi-
nistered via trained interviewer in the local language.
Interviewers were trained in the study protocol
including questionnaire and the objectives of the
study. Items on the questionnaire included: socio-
demographic characteristics of the respondents; travel
burden; support for adherence; the most frequently
used method to remember when to take ARVs at
scheduled times; ownership of a watch, a radio, or a
mobile phone; and adherence to ART. In order to
evaluate travel burden, time and cost for travel to the
ART sites were asked. We asked time for only one-
way trip, otherwise some respondents might include
waiting time at clinics as travel time. Adherence was
assessed by asking participants to report the number
of ARV doses missed in the past four days. Partici-
pants reporting any missed dose were classified in the
non-adherent group, while those reporting no missed
doses were classified in the adherent group. In
addition, respondents were asked about their
perceived fear of stigma resulting from taking ARVs
at home or work and feeling pressured to share ARVs
with someone, conditions that were sometimes ob-
served at the sites. The respondents verbally answered
all the items and the interviewers recorded their
answers. The respondents did not receive any financial
profit but did receive a small gift such as cooking oil.
Data analysis
Data were processed and analyzed in SPSS 15.0 for
Windows. A logistic regression model was used to
compute the relative risk of non-adherence, as
indicated by missed doses in the past four days.
A chi-square test was used to compare various
independent variables in proportions when appro-
priate. The relative risks of possible factors were
estimated by odds ratios (OR) and 95% confidence
intervals (CI). In a multivariable logistic regression
analysis, we included way to remember when to take
ARVs since this variable could be a specific social
factor to rural settings. And, independent variables
that had a significant relationship with dependent
variables at the pB0.05 level were selected and
included in the analysis.
Results
A total of 518 ART clients aged 18 and over from the
hospital and the rural health centers were asked to
participate in the study, and 518 (100%) agreed to
respond to the questionnaire.
The mean age of the respondents was 38.3 years
(range: 1872 years) and the average months of
treatment were 12.5 (range: 150 months) (Table 1).
Of the 518 respondents, 206 (40%) were male, 251
(49%) were married or remarried, 266 (51%) were
farmers, and 258 (50%) were treated by a rural health
center. Two hundred and sixty-two respondents
(51%) had a watch and 98 (19%) had a mobile
phone. In order to access an ART service, 166 (32%)
and 94 (18%) respondents spent more than two hours
on one-way travel and more than 10,000 Kwacha
(equivalent to 2.5 US$) on the return trip.
Four hundred and fifty-eight respondents (88%)
reported no missed doses during the last four days,
while 502 (97%) of respondents endorsed ‘‘comple-
tely’’ when asked if they understood the need to take
ARVs regularly at the same time. The most frequently
reported ways to remember when to take ARVs were a
watch (245, 47%) and a clock (79, 15%). Of note is the
fact that 49 of the respondents (10%) reported using
the position of the sun to remember when to take
ARVs. Eighty-four (16%) perceived fear of stigma
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Setting for ART
Total (n518)
District hospital
(n260)
Rural health centers
(n258) P-value
Average age (year) 38.2 (9.2 SD) 38.0 (9.1 SD) 38.6 (9.3 SD) 
Gender
Male 206 (39.8%) 112 (45.0%) 94 (37.0%) 0.069
Female 297 (57.3%) 137 (55.0%) 160 (63.0%)
Marital status
Single/Divorce/Widowed 248 (47.9%) 129 (52.4%) 119 (47.0%) 0.227
Married/Remarried 251 (48.5%) 117 (47.6%) 134 (53.0%)
Occupation
Government staff member 18 (3.5%) 16 (6.5%) 2 (0.8%) B0.001
Company employee 16 (3.1%) 12 (4.9%) 4 (1.7%)
Self-employed 68 (13.1%) 48 (19.6%) 20 (8.3%)
Farmer 266 (51.4%) 102 (41.6%) 164 (67.8%)
Housewife 53 (10.2%) 21 (8.6%) 32 (13.2%)
Other 66 (12.7%) 46 (18.8%) 20 (8.3%)
Which do you own
Watch 262 (50.6%) 138 (53.1%) 124 (48.1%) 0.254
Mobile phone 98 (18.9%) 66 (55.0%) 32 (55.0%) B0.001
Radio 254 (49.0%) 129 (49.6%) 125 (48.4%) 0.791
Television set 109 (21.0%) 83 (55.0%) 26 (55.0%) B0.001
Average treatment period
(month)
12.5 (10.3 SD) 15.2 (10.2 SD) 9.7 (9.7 SD)
Travel expenses for return trip
Free of charge 227 (43.8%) 83 (32.0%) 144 (56.7%) B0.001
Less than 10,000 Kw 192 (37.1%) 101 (39.0%) 91 (35.8%)
More than 10,000 Kw 94 (18.1%) 75 (29.0%) 19 (7.5%)
Understanding of need to take
ARVs
regularly at the same time
Yes, complete 502 (96.9%) 251 (96.5%) 251 (98.0%) 0.456
Yes, but incomplete 10 (1.9%) 7 (2.7%) 3 (1.2%)
No 6 (0.8%) 3 (0.8%) 3 (0.8%)
Way to remember when to take
ARVs
Watch 245 (47.3%) 123 (47.5%) 122 (47.4%) B0.001
Clock 79 (15.3%) 44 (16.9%) 35 (13.6%)
Mobile phone 58 (11.2%) 44 (16.9%) 14 (5.4%)
Radio/Television set 72 (13.9%) 20 (7.7%) 52 (20.2%)
Position of the sun 49 (9.5%) 20 (7.7%) 29 (11.3%)
Other 13 (2.5%) 8 (3.1%) 5 (1.9%)
Adherence support
None 99 (19.1%) 69 (26.5%) 30 (11.7%) B0.001
Family 264 (51.0%) 137 (52.7%) 127 (49.6%)
Other 153 (29.7%) 54 (20.8%) 99 (38.7%)
Perceived stigma of taking
ARVs
Never experienced stigma 432 (83.7%) 202 (78.0%) 230 (89.5%) B0.001
Experienced stigma 84 (16.3%) 57 (22.0%) 27 (10.5%)
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(10%) had felt pressured to share ARVs with someone
such as a family member or friend. About half of
the respondents (51%) received support for adherence
from their family members.
Bivariate analysis indicated that a younger age,
i.e., 38 years or younger (OR 2.5, 95% CI: 1.34.8,
p0.005), and higher travel expenses (OR2.3,
95% CI: 1.14.8, p0.022), were associated with
being classified in the non-adherent group (Table 2).
Perceived fear of stigma resulting from taking ARVs
at home or work (OR2.3, 95% CI: 1.2 to 4.5,
p0.011) and feeling pressured to share ARVs with
someone (OR 5.7, 95% CI: 2.9 to 11.4, pB0.001)
were also significantly associated with being classified
in the non-adherent group. In contrast, support for
adherence from family related to lower odds of being
classified in the non-adherence group in comparison
to some other form of support or no support
(OR0.4, 95% CI: 0.20.9, pB0.001).
Multivariable logistic regression analysis was
performed with age, cost of the return trip, support
for adherence, ways to remember when to take
ARVs, perceived fear of stigma resulting from taking
ARVs, and feeling pressured to share ARVs with
someone (Table 3). A multivariable model demon-
strated that age (38 or less; OR 2.6, 95% CI: 1.3
5.5, p0.009), ways to remember when to take ARVs
(the position of the sun) (OR 3.3, 95% CI: 1.38.8,
p0.016), and feeling pressured to share ARVs with
someone (OR 4.4, 95% CI: 1.612.0, p0.004)
were significantly associated with membership in the
non-adherent group.
We also found a high association between feeling
pressured to share ARVs and perceived fear of stigma
(OR20.7, 95% CI: 10.441.2, pB0.001) and
between higher travel expenses and perceived fear of
stigma (OR1.4, 95% CI: 1.11.7, p0.001).
Discussion
The current study investigated social factors and
considered possible conditions affecting the daily
lives of patients on ART in rural areas, as well as
socio-demographic characteristics related to ART
adherence in rural Zambia. Findings demonstrated
that age (38 years old or less), ‘‘remembering when to
take ARVs based on the position of the sun’’ and
‘‘feeling pressured to share ARVs with someone’’
were independent factors for being classified in the
non-adherent group. Given the lives of the partici-
pants in the study, conditions related to ART might
differ from those in urban areas. In fact, more than
half of respondents were farmers, about half did not
own a watch, and more than one-third did not use a
watch or a clock while nearly 10% used the position
of the sun to remember when to take ARVs. It is
suggested that PLWH in rural areas had limited ways
of knowing the exact time and ways to remember
when to take ARVs.
The distance to health care services in particular is
longer in rural areas than in urban areas (Perry and
Gesler 2000; Whetten et al., 2006). Therefore the
distance to ART services and travel expenses are well-
known barriers to optimal adherence in rural areas
(Grace et al., 1999; Reif et al., 2005; Stout et al.,
2004). However, Carlucci et al. (2008) reported that
patients in rural Zambia were able to achieve an
adherence rate compatible with good clinical out-
comes despite long-travel distances. In contrast, we
found a trend for high travel expenses to reach ART
services to be related to higher odds of classification
in the non-adherent group (OR 2.2, 95% CI: 0.9
5.2, p0.06), although it was not significant in
multivariable logistic regression analysis probably
because of the association with feeling pressured to
share ARVs.
Table 1 (Continued)
Setting for ART
Total (n518)
District hospital
(n260)
Rural health centers
(n258) P-value
Felt pressured to share ARVs
Never pressured 466 (90.5%) 230 (88.8%) 236 (92.2%) 0.191
Felt pressured 49 (9.5%) 29 (11.2%) 20 (7.8%)
Recent Adherence (missed
dose in the past four days)
Never missed 458 (88.4%) 233 (90.7%) 225 (88.6%) 0.441
One or more 53 (10.2%) 24 (9.3) 29 (11.4%)
834 I. Nozaki et al.Within the current structure of ARV services,
education and information about the importance of
taking ARVs at a specific dose time is delivered
frequently by health care providers. However,
whether this simple instruction is effective for people
living in rural areas, like those in the current study, is
questionable. Multivariable logistic regression analy-
sis showed that ‘‘remembering when to take ARVs
based on the position of the sun’’ was an independent
factor associated with higher odds of classification in
the non-adherent group although it was not signifi-
cant in bivariate analysis probably because of the
correlation with the adherence support from family
member. Health care providers should give rural
patients more applicable instructions in accordance
with their living conditions. More effective and
Table 2. Bivariate logistic regression analysis of correlates of non-adherence.
Missed dose in the past four days
One or more (n53) Never (n458) Odds ratio (95% CI) P-value
Age
More than 38 years 13 (24.5%) 205 (55.2%) Ref
38 years or less 40 (75.5%) 253 (44.8%) 2.493 (1.2994.787) 0.005
Gender
Male 15 (28.8%) 188 (42.3%) Ref
Female 37 (71.2%) 256 (57.7%) 1.812 (0.9663.401) 0.061
Marital status
Single/Divorce/
Widowed
30 (57.7%) 214 (48.5%) Ref
Married/Remarried 22 (42.3%) 227 (51.5%) 0.691 (0.3871.236) 0.211
Duration of ART
More than 12 months 30 (56.6%) 276 (60.3%) Ref
12 months or less 23 (43.4%) 182 (39.7%) 1.163 (0.6552.065) 0.607
Place of ART
District hospital 24 (45.3%) 233 (50.9%) Ref
Rural health center 29 (54.7%) 225 (49.1%) 1.251 (0.7072.215) 0.442
Cost of return trip
Free of charge 18 (36.0%) 204 (44.7%) Ref
Less than 10,000 Kw 16 (32.0%) 174 (38.2%) 1.043 (0.5162.105) 0.908
More than 10,000 Kw 16 (32.0%) 78 (17.1%) 2.325 (1.1294.787) 0.022
Way to remember when
to take ARVs
Watch 24 (46.2%) 220 (49.4%) Ref
Clock 8 (15.4%) 68 (15.3%) 1.078 (0.4632.511) 0.861
Mobile phone 2 (3.8%) 55 (13.4%) 0.333 (0.0761.453) 0.144
Radio/Television 10 (19.2%) 61 (13.7%) 1.503 (0.0623.312) 0.312
Position of the sun 8 (15.4%) 41 (9.2%) 1.789 (0.2451.256) 0.189
Adherence support
None 15 (10.3%) 84 (18.4%) Ref
Family 19 (35.8%) 241 (52.7%) 0.441 (0.2150.908) 0.026
Other 19 (35.8%) 123 (28.9%) 0.806 (0.3881.678) 0.563
Perceived stigma of
taking ARVs
Never experienced
stigma
37 (71.2%) 390 (85.2%) Ref
Experienced stigma 15 (28.8%) 68 (14.8%) 2.325 (1.2104.467) 0.011
Felt pressured to share
ARVs
Never pressured 36 (69.2%) 424 (92.8%) Ref
Felt pressured 17 (30.8%) 33 (7.2%) 5.710 (2.87211.353) B0.001
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times to offer patients should be identified and
included in the current strategies, and may result in
higher adherence in rural areas. In Thailand, for
instance, the national anthem, which is played at 8:00
and 18:00 every day on radio and TV, is successfully
used as a reminder for patients to take ARVs
(UNICEF, 2006).
The use of mobile phones has spread rapidly and
18% of participants owned it while they were in rural
area in our study. Collier et al. (2005) reported that
telephone call support was an effective way to
remember the time and to maintain a desirable level
of adherence in a research setting. And automated
reminding service using short message service (SMS)
is provided and favorably received in some countries.
For the people who own the mobile phone, interven-
tion using it could be considered in the future.
Feeling pressured to share ARVs with someone
such as a family member or friend, which nearly 10%
of the participants experienced, was the strongest
factor associated with being classified in the non-
adherent group in this study. This can also be an issue
for patients on ART in rural areas where ARVs are
not easily obtainable. Although participants were not
asked if they actually shared their medicine with
others, health care providers and counselors need to
be aware of this issue and to carefully monitor
patients in rural areas. A similar issue was the fear
of stigma resulting from taking ARVs at work or
home, which was experienced by 16% of participants
and significantly associated with being classified in
the non-adherent group in bivariate analysis. How-
ever, perceived fear of stigma resulting from taking
ARVs did not maintain significance in the multi-
variable analysis, probably because of the high
association with feeling pressured to share ARVs
with someone as confounding factor. Per Zambian
policy, ART patients must choose someone to
provide treatment support to maintain high adher-
ence to ART before starting the treatment, and most
choose a family member. The issues of feeling
pressured to share ARVs with a family member and
the fear of stigma resulting from taking ARVs at
home should be taken into careful consideration,
especially for female patients (Murray et al., 2009).
Education and counseling of family members should
be performed along with careful monitoring of
patients by health care providers.
One limitation of this study, however, is that
information was not collected from patients who
defaulted from treatment or untraceable patients
because this was conducted among who came to
health facility for treatment. Important findings in
Table 3. Multivariable logistic regression analysis of correlates of non-adherence.
Odds ratio (95% CI) P-value
Age
More than 38 years Ref
38 years or less 2.646 (1.2715.508) 0.009
Cost of return trip
Free of charge Ref
Less than 10,000 Kw 1.081 (0.5012.336) 0.842
More than 10,000 Kw 2.217 (0.9425.236) 0.068
Adherence support
None Ref
Family 0.538 (0.2261.282) 0.162
Other 1.176 (0.5042.747) 0.708
Way to remember when to take ARVs
Watch Ref
Clock 1.477 (0.5613.891) 0.43
Mobile phone 0.654 (0.1423.012) 0.585
Radio/Television 2.252 (0.9205.525) 0.076
Position of the sun 3.311 (1.2528.772) 0.016
Perceived stigma of taking ARVs
Never experienced stigma Ref
Experienced stigma 1.06 (0.4092.747) 0.905
Felt pressured to share ARVs
Never pressured Ref
Felt pressured 4.390 (1.61511.933) 0.004
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may be revealed by determining factors for low
adherence from patients lost to follow-up or their
reason for withdrawing from treatment.
The percentage of participants who had not
missed a dose in the past four days was 88%, which
was comparable to results of other studies using
similar questions (Gifford et al., 2000; Nemes et al.,
2004; Samet et al., 2004; Tesoriero et al., 2003).
Although optimal adherence is required for better
treatment outcomes for ART, there is still no ‘‘golden
standard’’ by which to measure adherence because
each methodology has its own advantages and
disadvantages (DiMatteo, 2004; Gill et al., 2005;
Oyugi et al., 2004). Self-report is most frequently
used measure of adherence to ART because it is
simple and inexpensive method. In addition, its
significant association with virological treatment
response has been reported (Nieuwkerk and Oort
2005; Simoni et al., 2006). Therefore, we adopted self-
report of missed doses in the past four days to
evaluate recent adherence.
As ART services expand to rural areas, informa-
tion of more specific factors arising in rural settings
can help program implementers because they may
differ from those in urban settings. Lessons learned in
urban settings must be cautiously applied to rural
areas because resources are limited in rural areas and
because of these factors. The current results show that
specific factors related to possible conditions occur-
ring in the daily lives of patients on ART in rural
Zambia are likely to affect adherence to treatment.
Conclusion
As ART services expand to rural areas, program
implementers should pay more attention to more
specific factors arising in rural settings since they may
differ from those in urban settings. This study
conducted in rural area, however, suggested that
specific factors such as remembering when to take
ARVs based on the position of the sun and feeling
pressured to share ARVs with someone, need to be
carefully considered along with demographic factors
as predictive factors for low adherence.
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